A5087382146- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Pediatric Hepatobiliary Diseases and Treatments
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- CAR-T cell therapy research
- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Immune cells in cancer
- Cancer Mechanisms and Therapy
- RNA modifications and cancer
- Head and Neck Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related Molecular Pathways
- Lung Cancer Treatments and Mutations
- interferon and immune responses
- Colorectal and Anal Carcinomas
- Monoclonal and Polyclonal Antibodies Research
- Epigenetics and DNA Methylation
- Bladder and Urothelial Cancer Treatments
Sun Yat-sen University
2018-2025
Sun Yat-sen University Cancer Center
2018-2025
Massachusetts General Hospital
2024-2025
Harvard University
2025
The First Affiliated Hospital, Sun Yat-sen University
2022-2024
State Key Laboratory of Oncology in South China
2018
Abstract A high rate of recurrence after curative therapy is a major challenge for the management hepatocellular carcinoma (HCC). Currently, no effective adjuvant available to prevent HCC recurrence. We designed personalized neoantigen-loaded dendritic cell vaccine and neoantigen-activated T-cell therapy, used it as treat 10 patients with who had undergone resection or radiofrequency ablation in first stage phase II trial (NCT03067493). The primary outcomes were safety neoantigen-specific...
Abstract Intrahepatic cholangiocarcinoma (ICC) has limited therapeutic options and a dismal prognosis. Adding blockade of the anti–programmed cell death protein (PD)-1 pathway to gemcitabine/cisplatin chemotherapy recently shown efficacy in biliary tract cancers but with low response rates. Here, we studied effects anti–cytotoxic T lymphocyte antigen (CTLA)-4 when combined anti–PD-1 orthotopic murine models ICC. This combination therapy led substantial survival benefits reduction morbidity...
Background. Immunotherapy is efficacious in hepatocellular carcinoma (HCC), but the benefits are limited to a minority of patients. Most HCC patients show resistance immune checkpoint blockade (ICB). Agonists stimulator interferon genes (STING), potent stimulators, showed effectiveness. Using preclinical models, we studied mechanisms ICB and STING agonism. Methods. Murine HCA-1 RIL-175 HCCs were orthotopically grown mice with underlying liver fibrosis, mimic presentation human HCC....
Single-longitudinal mode lasers are widely used as light sources in coherent lidars due to their narrow linewidth and long coherence length. However, we observed spontaneous frequency drift a single-longitudinal laser, accompanied by the oscillation of second mode, which could compromise laser’s performance. In this study, recorded resulting power fluctuations. By analyzing centroid positions laser spot, confirmed that originated from changes optical path To address issue, designed an...
The treatment strategy for management of Burkitt lymphoma (BL) has evolved during the past decades and clinical outcome this disease as a whole also improved. Due to limited information reported on survival trends patients with stage I/II (limited-stage) BL, here we used Surveillance, Epidemiology, End Results (SEER) database conduct our study. time period was divided into two eras (1983-2001 2002-2014) recent era reflected more intensive chemotherapy regimens, availability rituximab,...
The extranodal natural killer (NK)/T-cell lymphoma (NKTCL) of non-upper aerodigestive tract (NUAT) was found to have clinical heterogeneity compared with NKTCL the upper (UAT) in small scale studies. We conducted this study a much larger cohort analyze characteristics, prognostic factors, treatment modality, and outcomes patients NUAT-NKTCL.From January 2001 December 2017, total 757 were identified included study, including 92 NUAT-NKTCL (12.2%) 665 UAT-NKTCL (87.8%).NUAT-NKTCL had...
Background: Anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR mAbs), such as cetuximab and nimotuzumab have been used in the treatment of nasopharyngeal carcinoma (NPC), yet their efficacy safety are undetermined. Materials Methods: We performed two meta-analyses based on systematic searches PubMed, EMBASE, Cochrane Library SinoMed: comparison 1 (standard therapy plus mAbs vs. standard therapy) 2 (radiotherapy concurrent chemoradiotherapy) to explore value anti-EGFR NPC....
<p>Supplementary Fig. S7: Immunophenotyping in murine 425-ICC and SS49-ICC.</p>
<p>Supplementary Fig. S7: Immunophenotyping in murine 425-ICC and SS49-ICC.</p>
<p>Supplementary Fig. S7: Immunophenotyping in murine 425-ICC and SS49-ICC.</p>
<p>Supplementary Fig. S8: Bulk tissue RNA sequencing analysis of ICC after GC/dual ICB combination therapy in orthotopic murine 425-ICC model.</p>
<p>Supplementary Fig. S9: Expression levels of Cxcr3 and its ligands are increased in ICC tissues after GC/dual ICB treatment murine 425-ICC.</p>
<p>Supplementary Fig. S9: Expression levels of Cxcr3 and its ligands are increased in ICC tissues after GC/dual ICB treatment murine 425-ICC.</p>
<p>Supplementary Fig. S8: Bulk tissue RNA sequencing analysis of ICC after GC/dual ICB combination therapy in orthotopic murine 425-ICC model.</p>
<p>Supplementary Fig. S12: Effect of ICB treatment scheduling on efficacy and toxicity.</p>
<p>Supplementary Fig. S6: CTLA-4 blockade mediates the efficacy of GC/ICB therapy in ICC and increases CD8+CTL frequency murine ICC.</p>